Alimera Sciences traded at $5.45 this Friday July 1st, decreasing $0.02 or 0.37 percent since the previous trading session. Looking back, over the last four weeks, Alimera Sciences lost 10.51 percent. Over the last 12 months, its price fell by 39.58 percent. Looking ahead, we forecast Alimera Sciences to be priced at 5.11 by the end of this quarter and at 4.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
5.45
Daily Change
-0.37%
Yearly
-39.58%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.67 0.51 0.33% 33.43%
Aerie Pharmaceuticals 8.28 0.78 10.40% -48.28%
Applied Genetic Technologies 0.78 0.01 0.71% -81.18%
Alimera Sciences 5.45 -0.02 -0.37% -39.58%
Bayer 57.35 0.63 1.11% 11.42%
Insmed 20.73 1.01 5.12% -27.26%
Novartis 80.33 -0.52 -0.64% -4.96%
Iveric bio Inc. 9.31 -0.31 -3.22% 17.25%
Regeneron Pharmaceuticals 580.00 3.65 0.62% -0.62%
Roche Holding 320.40 1.85 0.58% -8.34%

Indexes Price Day Year
USND 11130 93.17 0.84% -23.97%
US2000 1728 20.57 1.20% -25.07%

Alimera Sciences
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.